Vaxcyte Inc Share Price Today: Live Updates & Key Insights

Vaxcyte Inc share price today is $54.65, up 1.37%. The stock opened at $53.765 against the previous close of $53.98, with an intraday high of $56.19 and low of $53.375.

Vaxcyte Inc Share Price Chart

Vaxcyte Inc

us-stock
To Invest in {{usstockname}}
us-stock

Vaxcyte Inc Share Price Performance

$54.65 0.0137(1.37%) PCVX at 23 Mar 2026 02:41 PM Biotechnology
Lowest Today 53.375
Highest Today 56.19
Today’s Open 53.765
Prev. Close 53.98
52 Week High 75.33
52 Week Low 27.66
Day’s Range: Low 53.375 High 56.19
52-Week Range: Low 27.66 High 75.33
1 day return -
1 Week return -1.65
1 month return -9.13
3 month return +13.67
6 month return +63.52
1 year return -25.89
3 year return +47.47
5 year return +131.28
10 year return -

Vaxcyte Inc Institutional Holdings

FMR Inc 9.61

HHG PLC 9.11

Vanguard Group Inc 8.47

RA Capital Management, LLC 7.45

BlackRock Inc 6.92

T. Rowe Price Investment Management,Inc. 5.78

Wellington Management Company LLP 4.15

State Street Corp 3.33

Vanguard Total Stock Mkt Idx Inv 3.10

Paradigm Biocapital Advisors LP 2.83

D. E. Shaw & Co LP 2.52

Westfield Capital Management Company, L.P. 2.46

Vanguard Health Care Inv 2.28

Vanguard Small Cap Index 2.23

JPMorgan Chase & Co 2.17

iShares Russell 2000 ETF 2.10

Deep Track Capital, LP 2.08

Kynam Capital Management, LP 2.03

Geode Capital Management, LLC 1.99

Janus Henderson Enterprise D 1.79

Janus Inst Mid Cap Growth CF 1.79

State Street® SPDR® S&P® Biotech ETF 1.56

T. Rowe Price US Mid-Cap Growth Equity 1.33

T. Rowe Price Mid-Cap Growth 1.33

Vanguard Small Cap Growth Index Inv 1.24

Adage Capital Partners Gp LLC 1.20

Caligan Partners LP 1.18

Fidelity Advisor Growth Opps M 1.18

T. Rowe Price Associates, Inc. 1.17

Polar Capital Holdings PLC 1.16

Eversept Partners, LP 0.99

T. Rowe Price Small-Cap Value 0.95

Vanguard Institutional Extnd Mkt Idx Tr 0.92

Fidelity Small Cap Index 0.78

Fidelity Select Health Care 0.75

iShares Russell 2000 Value ETF 0.74

Strategic Advisers Fidelity US TtlStk 0.72

Polar Capital Biotech S Inc 0.69

Janus Henderson Research D 0.69

Janus Henderson US Research Growth Eq 0.69

Vaxcyte Inc Market Status

Strong Buy: 9

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Vaxcyte Inc Fundamentals

Market Cap 7945.69 M

PB Ratio 2.8923

PE Ratio 0.0

Enterprise Value 6325.34 M

Total Assets 3045.97 M

Volume 3914888

Vaxcyte Inc Company Financials

Annual Revenue FY25:null 0.0M, FY24:0 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M

Annual Profit FY25:null 0.0M, FY24:null 0.0M, FY23:-10171000 -10.2M, FY22:null 0.0M, FY21:null 0.0M

Annual Net worth FY25:-766628000 -766.6M, FY24:-463927000 -463.9M, FY23:-402266000 -402.3M, FY22:-239640000 -239.6M, FY21:-100084000 -100.1M

Quarterly Revenue Q4/2025:null 0.0M, Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M

Quarterly Profit Q4/2025:4989000 5.0M, Q3/2025:null 0.0M, Q2/2025:-4989000 -5.0M, Q1/2025:null 0.0M, Q3/2024:-4503000 -4.5M

Quarterly Net worth Q4/2025:-246507000 -246.5M, Q3/2025:-212830000 -212.8M, Q2/2025:-166573000 -166.6M, Q1/2025:-140718000 -140.7M, Q3/2024:-103124000 -103.1M

About Vaxcyte Inc & investment objective

Company Information Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Organisation Biotechnology

Employees 507

Industry Biotechnology

CEO Mr. Grant E. Pickering M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Vaxcyte Inc FAQs

What is the share price of Vaxcyte Inc today?

The current share price of Vaxcyte Inc is $54.65.

Can I buy Vaxcyte Inc shares in India?

Yes, Indian investors can buy Vaxcyte Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Vaxcyte Inc shares in India?

You can easily invest in Vaxcyte Inc shares from India by:

Can I buy fractional shares of Vaxcyte Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Vaxcyte Inc?

Vaxcyte Inc has a market cap of $7945.69 M.

In which sector does Vaxcyte Inc belong?

Vaxcyte Inc operates in the Biotechnology sector.

What documents are required to invest in Vaxcyte Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Vaxcyte Inc?

The PE ratio of Vaxcyte Inc is N/A and the PB ratio is 2.89.